Rotavirus Vaccine

Aetna covers FDA‑approved rotavirus vaccines (RotaTeq [RV5] and Rotarix [RV1]) as medically necessary to prevent rotavirus gastroenteritis in infants and deems them experimental/investigational for other indications; some plans may exclude preventive services, so check benefit details. Dosing must follow FDA/ACIP guidance: start at 6 weeks (series should not be initiated after 14 weeks 6 days), minimum 4‑week intervals, RV5 is a 3‑dose series with the third dose before 32 weeks, RV1 is a 2‑dose series completed before 24 weeks, and all doses must be given by 8 months 0 days.

"RotaTeq contraindication: RotaTeq is contraindicated for infants with a serious allergic reaction to any vaccine component or to a previous dose of vaccine."

Sign up to see full coverage criteria, indications, and limitations.